1. Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant
2. Novavax. Novavax covid-19 vaccine demonstrates 89.3% efficacy in UK phase 3 trial. 28 Jan 2021. https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3
3. Johnson & Johnson. Johnson & Johnson announces single-shot Janssen covid-19 vaccine candidate met primary endpoints in interim analysis of its phase 3 ENSEMBLE trial. 29 Jan 2021. https://www.jnj.com/johnson-and-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints-in-interim-analysis-of-its-phase-3-ensemble-trial
4. Callaway E, Mallapaty S. Novavax offers first evidence that COVID vaccines protect people against variants. Nature 2020 Jan 29. https://www.nature.com/articles/d41586-021-00268-9
5. Badrinath P, Gupta A. Have we abandoned the Inglefinger rule in the COVID era? [electronic response to Wise J. Data transparency: “Nothing has changed since Tamiflu”. BMJ 2020. https://www.bmj.com/content/369/bmj.m2279/rr-1